Adjuvant treatment in patients at high risk of recurrence of thymoma: efficacy and safety of a three-dimensional conformal radiation therapy regimen. Conclusion: Adjuvant radiotherapy achieved good local control and showed an acceptable
toxicity profile in patients with high-risk thymomaRead More →

A Multidisciplinary Approach to Therapy for Unresectable Malignant Thymoma
Background: The therapeutic outcome for unresectable, locally advanced, malignant thymoma has been poor.
Objective: To improve tumor resectability and patient survival rates by studying a multimodal approach to therapy for unresectable malignant thymoma.Read More →

Carcinoma of Unknown Primary Site: Sequential Treatment with Paclitaxel/Carboplatin/Etoposide and Gemcitabine/Irinotecan: A Minnie Pearl Cancer Research Network Phase II Trial

Purpose. To evaluate the efficacy and toxicity of the
sequential administration of paclitaxel (Taxol®; BristolMyers Squibb; Princeton, NJ), carboplatin (Paraplatin®;
Bristol-Myers Squibb), and oral etoposide (VePesid®;
Bristol-Myers Squibb) followed by gemcitabine (Gemzar®;
Eli Lilly; Indianapolis, IN) and irinotecan (Campostar®;
Pfizer Pharmaceuticals; New York, NY) in the first-line
treatment of patients with carcinoma of unknown
primary site.
Read More →

Shortly before his death in 1995, Kenneth B. Schwartz, a cancer patient at Massachusetts General Hospital (MGH), founded The Kenneth B. Schwartz Center at MGH. The Schwartz Center is a nonprofit organization dedicated to supporting and advancing compassionate health care delivery, which provides hope to the patient and support to caregivers and encourages the healing process. The center sponsors the Schwartz Center Rounds, a monthly multidisciplinary forum where caregivers reflect on important psychoso- cial issues faced by patients, their families, and their caregivers, and gain insight and support from fellow staff members.

Read More →

Two Cases of Thymic Carcinoma Initially Presenting as Bone Metastasis: A Clinical Report and the Usefulness of CD5 Immunohistochemistry for Assessing Bone LesionsRead More →

American Society of Clinical Oncology Technology Assessment: Chemotherapy Sensitivity and Resistance Assays

To develop a technology assessment of chemotherapy sensitivity and resistance assays in order to
define the role of these tests in routine oncology practice.
Read More →

Thymomas and thymic carcinoma are rare neoplasms. Surgical resection is the cornerstone of effective therapy. Stage I disease is effectively treated by complete surgical resection. The role of radiation therapy in completely resected stage II disease remains controversial. Adjuvant radiation therapy is useful for local control and may improve survival in patients with incompletely resected tumours. Cisplatin-based chemotherapy regimens play an important role in the treatment of advanced stage III/IV or recurrent disease thymomas, but have proven less effective for thymic carcinoma. Phase II trials of multimodality therapy incorporating neoadjuvant chemotherapy, surgery and postoperative radiation therapy show promise for unresectable disease. This review discusses recent clinical data and the potential role for agents targeting the epidermal growth factor receptor, angiogenesis and apoptotic pathways.Read More →

Carcinoma showing thymus-like differentiation (CASTLE) is a rare tumor that occurs in the soft tissue of the neck or in the thyroid gland. We report a case of CASTLE in a 54-year-old man presenting with hoarseness. Computed tomography (CT) and magnetic resonance imaging (MRI) showed a mass enclosing the right carotid artery with the shape of lobulation and invasion to the trachea. The mass was hypointense on T1-weighted imaging and, on T2-weighted imaging, showed a hyperintense periphery with isointense center relative to muscle. In dynamic MRI, the mass revealed gradual but slight heterogeneous enhancement from the periphery. Diagnosis was confirmed by histopathology.Read More →

Clinical and immunohistochemical study of eight cases with thymic carcinoma
Conclusions: In this small series, it is suggested that a complete resection suggests a favorable
result. Immunohistochemical results reveal that the expression of these proteins might indicate the
aggressiveness of thymic carcinoma.
Thymic carcinoma is a rare type of malignant tumor [1,2].
It is more invasive and with a poorer prognosis than Thymoma.Read More →